Holen Sie sich die Stockscreener-App
2.40
1.69%
0.04
Handel nachbörslich:
2.47
0.07
+2.92%
Schlusskurs vom Vortag:
$2.36
Offen:
$2.37
24-Stunden-Volumen:
13,372
Relative Volume:
1.72
Marktkapitalisierung:
$15.32M
Einnahmen:
$105.38M
Nettoeinkommen (Verlust:
$17.78M
KGV:
0.8989
EPS:
2.67
Netto-Cashflow:
$-50.48M
1W Leistung:
-2.04%
1M Leistung:
+8.34%
6M Leistung:
-5.88%
1J Leistung:
-14.29%
1-Tages-Spanne:
$2.3601
$2.52
1-Wochen-Bereich:
$2.32
$3.15
52-Wochen-Spanne:
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
Firmenname
Mei Pharma Inc
Sektor
Branche
Telefon
858-369-7100
Adresse
11455 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie MEIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.40 | 15.32M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Herabstufung | Laidlaw | Buy → Hold |
| 2022-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-03-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | Eingeleitet | Jefferies | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-29 | Eingeleitet | SunTrust | Buy |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-07-27 | Hochstufung | Stifel | Hold → Buy |
| 2018-07-13 | Eingeleitet | SunTrust | Buy |
| 2016-04-18 | Bestätigt | Wedbush | Neutral |
| 2015-03-23 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-18 | Bestätigt | ROTH Capital | Buy |
| 2014-10-16 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Brean Capital | Buy |
| 2013-10-22 | Bestätigt | Stifel | Buy |
| 2013-04-15 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mei Pharma Inc Aktie (MEIP) Neueste Nachrichten
MEI Pharma (NASDAQ:MEIP) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Northern Trust Corp Increases Stock Holdings in MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
MEI Pharma Reports Significant Revenue Decline - TipRanks
MEIP Explores Strategic Options to Enhance Shareholder Value | M - GuruFocus
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - GuruFocus
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
Inside Buffett’s $334B Cash Pile: Get Ready for Berkshire Hathaway Earnings - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Sharp Co. (OTCMKTS:SHCAY) Short Interest Down 25.8% in March - The AM Reporter
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
Billionaire David Tepper’s Top 10 Stock Picks - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Will the Stock Market Crash As President Trump's Tariffs Take Effect? History Offers a Clue. - The Globe and Mail
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Cautious Investors Should Wait for THIS Entry Point Before Buying Nvidia Stock - The Globe and Mail
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
Finanzdaten der Mei Pharma Inc-Aktie (MEIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):